Clinical Trial

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated February 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. The main questions it aims to answer are: * Does the investigational drug BL0175 is safe for participants after dosed -multiple times? * Which is the highest safety dose of BL0175 after multiple dose? * What medical problems do participants have when using BL0175? * Does the investigational drug BL0175 works for participants after dosed -multiple times?
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-16; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2025-07-11
Trial Details
NCT Number NCT06738966
Lead Sponsor Shanghai Best-Link Bioscience, LLC
Conditions Breast Cancer, Ovarian Cancer, Endometrial Cancer
Enrollment 9 participants
Start Date 2025-03-10
Primary Completion 2026-02-20 (estimated)
Study Completion 2027-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-01-13